- Abstract
- Core Tip
- Article Highlights
- Full Article (PDF)
- Full Article with Cover (PDF)
- Full Article (XML)
- Full Article (HTML)
- Audio
- PubMed Central
- PubMed
- CrossRef
- Google Scholar
- Similar Articles (25)
- Timeline of Article Publication (8)
- Authors Evaluation (1)
- Article Quality Tracking (0)
- Reference Citation Analysis (6)
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4655)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jan 28, 2024 (publication date) through Apr 9, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Cao YZ, Zheng GL, Zhang TQ, Shao HY, Pan JY, Huang ZL, Zuo MX. Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis. World J Gastroenterol 2024; 30(4): 318-331 [PMID: 38313229 DOI: 10.3748/wjg.v30.i4.318] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v30/i4/318.htm |
| Number | Citing Articles |
| 1 |
Liyuan Hao, Shenghao Li, Fanghang Ye, Hengyi Wang, Yuxin Zhong, Xiaoyi Zhang, Xiaoyu Hu, Xiaopeng Huang. The current status and future of targeted-immune combination for hepatocellular carcinoma. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1418965
|
| 2 |
Andrzej S Tarnawski. Editor-in-Chief articles of choice and comments from January to June 2024. World Journal of Gastroenterology 2024; 30(34): 3875-3882 doi: 10.3748/wjg.v30.i34.3875
|
| 3 |
Yu-zhe Cao, Jia-yu Pan, Guang-lei Zheng, Chao An, Meng-Xuan Zuo. Hepatic arterial infusion chemotherapy combined with systemic therapy sequentially or simultaneously for advanced hepatocellular carcinoma. Cancer Immunology, Immunotherapy 2024; 74(1) doi: 10.1007/s00262-024-03872-6
|
| 4 |
Kristin E. Goodsell, Alice J. Tao, James O. Park. Neoadjuvant therapy for hepatocellular carcinoma—priming precision innovations to transform HCC treatment. Frontiers in Surgery 2025; 12 doi: 10.3389/fsurg.2025.1531852
|
| 5 |
Georgia Sofia Karachaliou, Nikolaos Dimitrokallis, Dimitrios P Moris. Downstaging strategies for unresectable hepatocellular carcinoma. World Journal of Gastroenterology 2024; 30(20): 2731-2733 doi: 10.3748/wjg.v30.i20.2731
|
| 6 |
Peng Tang, Fei Zhou. Efficacy and safety of PD-1/PD-L1 inhibitors combined with tyrosine kinase inhibitors as first-line treatment for hepatocellular carcinoma: a meta-analysis and trial sequential analysis of randomized controlled trials. Frontiers in Pharmacology 2025; 16 doi: 10.3389/fphar.2025.1535444
|
| 7 |
Hengzhou Zhu, Wenyue Zhao, Haoyan Chen, Xiaodan Zhu, Jianliang You, Chunhui Jin. Evaluation of the effectiveness and safety of combining PD-1/PD-L1 inhibitors with anti-angiogenic agents in unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1468440
|
| 8 |
Kyoko Oura, Asahiro Morishita, Tomoko Tadokoro, Koji Fujita, Joji Tani, Hideki Kobara. Immune Microenvironment and the Effect of Vascular Endothelial Growth Factor Inhibition in Hepatocellular Carcinoma. International Journal of Molecular Sciences 2024; 25(24): 13590 doi: 10.3390/ijms252413590
|